Terms: = Colorectal cancer AND PR, PGR, progesterone receptor AND Treatment
616 results:
1. The association of preoperative radiotherapy and surgery for AJCC stage I-III rectal adenocarcinoma: a population-based study.
Wang Y; Zhu X; Pan W; Li Z; Hu Z; Hou B; Meng H
BMC Surg; 2024 Oct; 24(1):280. PubMed ID: 39354419
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of pathological response and lymph node metastasis after neoadjuvant therapy in rectal cancer through tumor and mesorectal MRI radiomic features.
Qin S; Liu K; Chen Y; Zhou Y; Zhao W; Yan R; Xin P; Zhu Y; Wang H; Lang N
Sci Rep; 2024 Sep; 14(1):21927. PubMed ID: 39304726
[TBL] [Abstract] [Full Text] [Related]
3. Effects of Degreasing Pretreatment on Immunohistochemistry and Molecular Analysis of Gastrointestinal and Breast cancer Samples.
Jin S; Wu D; Zhang Y; Tang H; Yu J; Zhang J; Li X; Liu Y; Yang J; Zhang T; Hu M; Li X; Xiao S; Yue J; Wang M
Lab Invest; 2024 Sep; 104(9):102125. PubMed ID: 39168250
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.
Huang Z; Li C; Huang Y; Liang W; Tao H
Front Immunol; 2024; 15():1425596. PubMed ID: 39100666
[TBL] [Abstract] [Full Text] [Related]
5. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic implications of immunohistochemistry in patients with endometrial cancer.
Anca-Stanciu MB; Manu A; Olinca MV; Coroleucă BC; Comandaşu DE; Coroleucă CA; Maier C; Brătilă E
Rom J Morphol Embryol; 2024; 65(2):185-193. PubMed ID: 39020532
[TBL] [Abstract] [Full Text] [Related]
7. Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade.
Qin S; Chen Y; Liu K; Li Y; Zhou Y; Zhao W; Xin P; Wang Q; Lu S; Wang H; Lang N
Cancer Radiother; 2024 Aug; 28(4):341-353. PubMed ID: 38981746
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Chen H; Zhang JH; Hao Q; Wu XL; Guo JX; Huang CX; Zhang J; Xing GS; An ZL; Ling Y; Zhao JG; Bao YN
Int J Colorectal Dis; 2024 Jun; 39(1):99. PubMed ID: 38926205
[TBL] [Abstract] [Full Text] [Related]
9. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
10. Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes.
Soomro MY; Khan SR; Muhammad H; Ahmad S; Zehra N; Ali I; Samar MR; Hameed A; Moosajee M; Rashid YA
BMC Cancer; 2024 Apr; 24(1):479. PubMed ID: 38627736
[TBL] [Abstract] [Full Text] [Related]
11. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Outcomes of Self-Expandable Metallic Stents as a Bridge to Surgery for Obstructive and Symptomatic Primary Tumors of Stage IV colorectal cancer: A Propensity-Score Analysis.
Sekioka A; Ota S; Ito T; Mizukami Y; Tsuboi K; Okamura M; Lee Y; Ishida S; Shim Y; Adachi Y
J Laparoendosc Adv Surg Tech A; 2024 Jul; 34(7):561-567. PubMed ID: 38574310
[No Abstract] [Full Text] [Related]
13. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
[TBL] [Abstract] [Full Text] [Related]
14. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract] [Full Text] [Related]
15. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
[TBL] [Abstract] [Full Text] [Related]
16. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
17. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
18. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
Kikuchi K; Ogawa M; Sasaki A
J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract] [Full Text] [Related]
20. Validity assessment of the POLARS score tool in the prediction of post rectal cancer surgery LARS score in a population-based Swedish cohort.
Rethy B; Nordenvall C; Pieniowski E; Jansson-Palmer G; Johar A; Lagergren P; Abraham-Nordling M
BMJ Open Gastroenterol; 2024 Jan; 11(1):. PubMed ID: 38199776
[TBL] [Abstract] [Full Text] [Related]
[Next]
